These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38164115)

  • 1.
    Ciccullo A; Iannone V; Lombardi F; Borghetti A; Di Giambenedetto S
    AIDS Res Hum Retroviruses; 2024 Oct; 40(10):555-556. PubMed ID: 38164115
    [No Abstract]   [Full Text] [Related]  

  • 2. A HIV Superinfection Diagnosed in a Patient on Intramuscular Long-acting Combination of Cabotegravir and Rilpivirine.
    Valin N; Lambert-Niclot S; Torres E; Meynard JL; Périllaud-Dubois C; Morand-Joubert L; Lacombe K
    Clin Infect Dis; 2024 Jul; 79(1):196-197. PubMed ID: 38513236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine.
    Mazzitelli M; Avolio A; Carandina R; Parisi S; Wensing A; Cattelan A
    J Antimicrob Chemother; 2024 Aug; 79(8):2074-2076. PubMed ID: 38905150
    [No Abstract]   [Full Text] [Related]  

  • 4. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy.
    Brock JB; Herrington P; Hickman M; Hickman A
    Clin Infect Dis; 2024 Jan; 78(1):122-124. PubMed ID: 37740255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementing long-acting injectable cabotegravir and rilpivirine in Africa.
    Orkin C; Ring K
    Lancet Infect Dis; 2024 Oct; 24(10):1060-1061. PubMed ID: 38821072
    [No Abstract]   [Full Text] [Related]  

  • 7. Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience.
    Castelli A; Lanzafame M; Morra M; Bertoldi M; Delama A; Fait D; Vento S
    AIDS Res Hum Retroviruses; 2024 May; 40(5):283-285. PubMed ID: 37776179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine.
    Ripamonti D; Borghetti A; Zazzi M
    J Antimicrob Chemother; 2024 Oct; 79(10):2720-2724. PubMed ID: 39066658
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
    Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
    Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
    Lowenthal ED; Chapman J; Ohrenschall R; Calabrese K; Baltrusaitis K; Heckman B; Yin DE; Agwu AL; Harrington C; Van Solingen-Ristea RM; McCoig CC; Adeyeye A; Kneebone J; Chounta V; Smith-Anderson C; Camacho-Gonzalez A; D'Angelo J; Bearden A; Crauwels H; Huang J; Buisson S; Milligan R; Ward S; Bolton-Moore C; Gaur AH; ;
    Lancet HIV; 2024 Apr; 11(4):e222-e232. PubMed ID: 38538161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label Use of Long-Acting Injectable Antiretroviral Therapy: A Single Center Retrospective Review of Youth Living With HIV With Detectable HIV RNA Starting Injectable Therapy.
    Rousseau A; McGrath E; Benjamins L; Cockern S; Meade J; Houston K; Breaux M; Secord E
    J Pediatric Infect Dis Soc; 2024 May; 13(5):285-287. PubMed ID: 38591356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals.
    Cossu MV; Cattaneo D; Moschese D; Giacomelli A; Soloperto S; D'Avolio A; Antinori S; Gori A; Rizzardini G; Gervasoni C
    J Antimicrob Chemother; 2024 May; 79(5):1126-1132. PubMed ID: 38530862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reply to Cossu et al., "Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV".
    Han K
    Antimicrob Agents Chemother; 2024 May; 68(5):e0020424. PubMed ID: 38534102
    [No Abstract]   [Full Text] [Related]  

  • 14. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
    Kityo C; Mambule IK; Musaazi J; Sokhela S; Mugerwa H; Ategeka G; Cresswell F; Siika A; Kosgei J; Shah R; Naidoo L; Opiyo K; Otike C; Möller K; Kaimal A; Wambui C; Van Eygen V; Mohammed P; Addo Boateng F; Paton NI;
    Lancet Infect Dis; 2024 Oct; 24(10):1083-1092. PubMed ID: 38821073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient Viremia in Young Adults With HIV After the Switch to Long-Acting Cabotegravir and Rilpivirine: Considerations for Dosing Schedule and Monitoring.
    Rakhmanina N; Richards K; Adeline Koay WL
    J Acquir Immune Defic Syndr; 2023 Mar; 92(3):e14-e17. PubMed ID: 36480701
    [No Abstract]   [Full Text] [Related]  

  • 16. Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection.
    Calleja-Hernández MÁ; Martinez-Sesmero JM; Vallejo-Aparicio LA; Hernández-Novoa B; Badia X
    Farm Hosp; 2022 Jul; 46(4):208-214. PubMed ID: 36183218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV.
    Cossu MV; D'Avolio A; Gervasoni C; Giacomelli A; Cattaneo D; Moschese D
    Antimicrob Agents Chemother; 2024 May; 68(5):e0017524. PubMed ID: 38534104
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings.
    Jonsson-Oldenbüttel C; Ghosn J; van der Valk M; Florence E; Vera F; De Wit S; Rami A; Bonnet F; Hocqueloux L; Hove K; Ait-Khaled M; DeMoor R; Bontempo G; Latham CL; Gutner CA; Iyer S; Gill M; Czarnogorski M; D'Amico R; van Wyk J
    J Acquir Immune Defic Syndr; 2024 Aug; 96(5):472-480. PubMed ID: 38985445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine.
    Rubenstein E; Diemer M; Goldwirt L; Lascoux-Combe C; Chaix ML; Rami A; Ponscarme D; Lafaurie M; Denis B; De Castro N; Gras J; Liegeon G; Sellier PO; Deville L; Chevret S; Delaugerre C; Molina JM
    AIDS; 2024 Jul; 38(8):1267-1269. PubMed ID: 38814715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary on 'Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net)'.
    Sah S; Verma A; Zahiruddin QS; Rustagi S
    HIV Med; 2024 Oct; 25(10):1177-1178. PubMed ID: 39091145
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.